Navigation Links
DUSA Pharmaceuticals, Inc.(R) to Host First Quarter 2010 Corporate Highlights and Financial Results Conference Call
Date:5/6/2010

WILMINGTON, Mass., May 6 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc. ( DUSA) announces that its corporate highlights and first quarter financial results press release will be issued on Tuesday, May 11th at 6:30 a.m. to be followed by a conference call at 8:30 a.m.

Tuesday, May 11th - 8:30 a.m. E.T.

If calling from North America use the following toll-free number:

800-647-4314

International callers use:

502-719-4466

Password - DUSA

A replay of the call will be available approximately 15 minutes following the call

North American callers: 877-863-0350

International callers: 858-244-1268

The call will be accessible on our web site approximately four hours following the call at www.dusapharma.com.

About DUSA Pharmaceuticals

DUSA Pharmaceuticals, Inc. is a specialty pharmaceutical company focused primarily on the development and marketing of its Levulan® photodynamic therapy (PDT) technology platform, for dermatological conditions.  Levulan® PDT is currently approved for the treatment of Grade 1 and 2 actinic keratoses (AKs) of the face and scalp.  DUSA is researching the use of Levulan® PDT to prevent AKs and squamous cell carcinomas in immunosuppressed solid organ transplant recipients and is supporting research related to oral leukoplakia in collaboration with the National Institutes of Health (NIH).  DUSA also markets other dermatology products, including ClindaReach®.  DUSA is based in Wilmington, Mass.  Please visit our website at www.dusapharma.com.


'/>"/>
SOURCE DUSA Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Epix Pharmaceuticals, Inc. Announces the May 28, 2010 Auction Sale of EP-3600 MRI Imaging Agent
2. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Resolves Investigation of Past TOPAMAX(R) Marketing and Promotional Activities
3. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Agrees to $75 Million Settlement for Topamax(R) False Claims Lawsuit
4. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2009 Financial Results
5. Ampio Pharmaceuticals, Inc. Retains Redwood Consultants, LLC to Assist in Shareholder Relations and Strategic Planning
6. Chay Enterprises Inc. Completes Merger With Repurposed Drug Developer Ampio Pharmaceuticals, Inc.
7. Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2009 Financial Results
8. GlaxoSmithKline President of North America Pharmaceuticals, Deirdre Connelly, Named 2010 Woman of the Year by the Healthcare Businesswomens Association
9. Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
10. China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009
11. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , December 5, 2016 PharmaBoardroom today releases ... . ... This report offers companies, investors, policymakers, and stakeholders crucial insight ... of Europe , home to some of the world,s ... pharmaceutical companies in Novartis and Roche, and with a number one ranking ...
(Date:12/5/2016)... and TAIPEI, Taiwan , Dec. 5, 2016 ... treatment ropeginterferon alfa-2b showed non-inferiority to hydroxyurea (HU) in Complete ... better safety and tolerability profile of ropeginterferon alfa-2b versus HU ... and the ongoing long-term follow-up trial CONTINUATION-PV to obtain European ... intends to present this data to the FDA as it ...
(Date:12/4/2016)... Attorney General of Louisiana , Charles ... firm of Kahn Swick & Foti, LLC ("KSF"), announces that ... LCI ). On November 3, ... in Generic-Drug Probe to Be Filed by Year-End," which reported ... two years ago, now spans more than a dozen companies," ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... December 05, 2016 , ... As renowned, board-certified dermatologists, Dr. Sabrina G. Fabi ... patients who do not do their research and undergo cosmetic dermatology treatments from unqualified ... midst of a renaissance and every other month a new treatment or device is ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... CardioQuick Patch® significantly improves the reproducibility and accuracy of placing precordial electrodes with ... , Over the last 60 years, studies have shown that single electrode ...
(Date:12/4/2016)... ... ... James Earl Jones is known for myriad roles on stage and screen, he has ... the forthcoming episodes examines mammogram techniques; a very important part of preventative medicine. , ... detection. Like any other disease, treatments have a much higher chance of success if ...
(Date:12/4/2016)... ... December 04, 2016 , ... Patients who wish to gain ... of a cosmetic procedure known as Carbon Dioxide (C02) Fractional Laser Resurfacing ... age spots, fine lines, uneven coloration, wrinkles, scarring, skin laxity or textural ...
(Date:12/2/2016)... ... 02, 2016 , ... Lori G. Cohen and Sara K. ... at the American Conference Institute’s 21st Drug & Medical Device Litigation Conference , ... of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical Device & Health ...
Breaking Medicine News(10 mins):